We are live on ! Find out more
Daiwa Securities Group

Daiwa Securities Group Portfolio holdings

AUM $34.8B
1-Year Est. Return 20.7%
This Fund
S&P 500
This Quarter Est. Return
+9.61%
1 Year Est. Return
+20.7%
3 Year Est. Return
+66.64%
5 Year Est. Return
+79.21%
10 Year Est. Return
+192.59%
AUM
$21.6B
AUM Growth
+$2.85B
Cap. Flow
+$1.11B
Cap. Flow %
5.1%
Top 10 Hldgs %
30.93%
Holding
1,357
New
41
Increased
770
Reduced
236
Closed
79

Top Sells

Rank Stock Value
1
TSLA icon
Tesla
TSLA
+$188M
2
SNOW icon
Snowflake
SNOW
+$152M
3
IRM icon
Iron Mountain
IRM
+$149M
4
PLD icon
Prologis
PLD
+$131M
5
AMT icon
American Tower
AMT
+$100M

Sector Composition

Rank Sector Weight
1 Real Estate 41.83%
2 Technology 20.16%
3 Communication Services 6.63%
4 Financials 5.64%
5 Consumer Discretionary 5.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CVAC
1201
DELISTED
CureVac
CVAC
$2K ﹤0.01%
697
FDMT icon
1202
4D Molecular Therapeutics
FDMT
$515M
$2K ﹤0.01%
184
HCM icon
1203
HUTCHMED
HCM
$1.93B
$2K ﹤0.01%
85
HUMA icon
1204
Humacyte
HUMA
$170M
$2K ﹤0.01%
301
KALV
1205
DELISTED
KalVista Pharmaceuticals
KALV
$2K ﹤0.01%
154
LXRX icon
1206
Lexicon Pharmaceuticals
LXRX
$1.04B
$2K ﹤0.01%
1,369
MLYS icon
1207
Mineralys Therapeutics
MLYS
$2.38B
$2K ﹤0.01%
152
OABI icon
1208
OmniAb
OABI
$286M
$2K ﹤0.01%
475
PACB icon
1209
Pacific Biosciences
PACB
$432M
$2K ﹤0.01%
909
-234,399
-100% -$385K
PLRX icon
1210
Pliant Therapeutics
PLRX
$66.3M
$2K ﹤0.01%
196
PRME icon
1211
Prime Medicine
PRME
$558M
$2K ﹤0.01%
398
REPL icon
1212
Replimune Group
REPL
$449M
$2K ﹤0.01%
200
RGNX icon
1213
Regenxbio
RGNX
$615M
$2K ﹤0.01%
146
SAGE
1214
DELISTED
Sage Therapeutics
SAGE
$2K ﹤0.01%
239
SIGA icon
1215
SIGA Technologies
SIGA
$240M
$2K ﹤0.01%
270
SLRN
1216
DELISTED
ACELYRIN
SLRN
$2K ﹤0.01%
398
SRRK icon
1217
Scholar Rock
SRRK
$5.92B
$2K ﹤0.01%
208
SVRA icon
1218
Savara
SVRA
$1.09B
$2K ﹤0.01%
553
TBPH icon
1219
Theravance Biopharma
TBPH
$875M
$2K ﹤0.01%
215
+200
+1,333% +$1.73K
THRD
1220
DELISTED
Third Harmonic Bio
THRD
$2K ﹤0.01%
149
TRML
1221
DELISTED
Tourmaline Bio
TRML
$2K ﹤0.01%
95
URGN icon
1222
UroGen Pharma
URGN
$1.99B
$2K ﹤0.01%
160
+112
+233% +$1.66K
YMAB
1223
DELISTED
Y-mAbs Therapeutics
YMAB
$2K ﹤0.01%
162
RVNC
1224
DELISTED
Revance Therapeutics, Inc.
RVNC
$2K ﹤0.01%
331
ALEC icon
1225
Alector
ALEC
$169M
$1K ﹤0.01%
277

Similar funds

Daiwa Securities Group's Q3 2024 Portfolio in Review

As of Q3 2024, Daiwa Securities Group held 1,357 positions worth $21.6B, up 15% from $18.8B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Daiwa Securities Group deployed $1.11B of net new capital in Q3 2024, opening 41 new positions and adding to 770 existing holdings. Its largest new stake was Lineage Inc: 465,245 shares worth $36.5M.

By sector, the portfolio is most concentrated in Real Estate at 42% of assets, down from 42% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Tesla, an estimated $188M trimmed.

  • Daiwa Securities Group's largest Q3 2024 buy was Lineage Inc: 465,245 shares worth $36.5M.
  • Daiwa Securities Group added most to CrowdStrike in Q3 2024, an estimated $203M increase.
  • Daiwa Securities Group's biggest Q3 2024 reduction was Tesla, cutting an estimated $188M.
  • Daiwa Securities Group fully exited Lam Research in Q3 2024, selling an estimated $26.6M.
  • Daiwa Securities Group's ten largest holdings make up 31% of its $21.6B portfolio in Q3 2024.
  • Daiwa Securities Group opened 41 new positions and closed 79 in Q3 2024.
  • Daiwa Securities Group's portfolio value rose 15% quarter-over-quarter to $21.6B.

Based on Daiwa Securities Group's 13F filing for Q3 2024, filed 12 Nov 2024.